Focus: Biomea Fusion is a public biotech company focused on small molecule therapeutics targeting cancer and metabolic diseases. Founded in 2017 and headquartered in San Carlos, CA, the company is in early-stage clinical development with no approved products.
Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Biomea Fusion to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Biomea Fusion
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Biomea Fusion's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Biomea Fusion shows promising diabetes and obesity drug data, expands Phase I study for weight loss therapy. - Pluang
Biomea Fusion shows promising diabetes and obesity drug data, expands Phase I study for weight loss therapy. Pluang
B-Cell Non-Hodgkin Lymphoma Pipeline 2026: Therapies Under - openPR.com
B-Cell Non-Hodgkin Lymphoma Pipeline 2026: Therapies Under openPR.com
Oppenheimer Remains a Buy on Gilead Sciences (GILD) - The Globe and Mail
Oppenheimer Remains a Buy on Gilead Sciences (GILD) The Globe and Mail
BMS and Hengrui forge $15.2bn alliance for early-stage drugs - Pharmaceutical Technology
BMS and Hengrui forge $15.2bn alliance for early-stage drugs Pharmaceutical Technology
Biomea Fusion to present diabetes drug icovamenib data at ADA 2026 conference - Pluang
Biomea Fusion to present diabetes drug icovamenib data at ADA 2026 conference Pluang
Biomea reports positive type 1 diabetes trial results - Investing.com
Biomea reports positive type 1 diabetes trial results Investing.com
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo